NasdaqCM - Delayed Quote • USD
Seelos Therapeutics, Inc. (SEEL)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:41 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
40,499.0000
40,499.0000
70,916.0000
61,669.0000
18,759.0000
Operating Income
-40,499.0000
-40,499.0000
-70,916.0000
-61,669.0000
-18,759.0000
Net Non Operating Interest Income Expense
123.0000
123.0000
107.0000
-1,485.0000
-119.0000
Other Income Expense
2,494.0000
2,494.0000
-2,725.0000
-2,894.0000
-223.0000
Pretax Income
-37,882.0000
-37,882.0000
-73,534.0000
-66,048.0000
-19,101.0000
Net Income Common Stockholders
-37,882.0000
-37,882.0000
-73,534.0000
-66,048.0000
-19,101.0000
Diluted NI Available to Com Stockholders
-37,882.0000
-37,882.0000
-73,534.0000
-66,048.0000
-19,101.0000
Basic EPS
-7.73
-7.73
-20.74
-21.90
-12.90
Diluted EPS
-7.73
-7.73
-20.74
-21.90
-12.90
Basic Average Shares
4,900.2220
4,900.2220
3,545.6910
3,029.6680
1,492.2210
Diluted Average Shares
4,900.2220
4,900.2220
3,545.6910
3,029.6680
1,492.2210
Total Operating Income as Reported
-40,499.0000
-40,499.0000
-70,916.0000
-61,669.0000
-18,759.0000
Total Expenses
40,499.0000
40,499.0000
70,916.0000
61,669.0000
18,759.0000
Net Income from Continuing & Discontinued Operation
-37,882.0000
-37,882.0000
-73,534.0000
-66,048.0000
-19,101.0000
Normalized Income
-42,425.0000
-42,425.0000
-73,826.0000
-62,924.0000
-18,878.0000
Interest Income
198.0000
198.0000
121.0000
113.0000
45.0000
Interest Expense
75.0000
75.0000
14.0000
1,598.0000
164.0000
Net Interest Income
123.0000
123.0000
107.0000
-1,485.0000
-119.0000
EBIT
-37,807.0000
-37,807.0000
-73,520.0000
-64,450.0000
-18,937.0000
EBITDA
-37,750.0000
-37,750.0000
-73,467.0000
-64,450.0000
-18,937.0000
Reconciled Depreciation
57.0000
57.0000
53.0000
--
--
Net Income from Continuing Operation Net Minority Interest
-37,882.0000
-37,882.0000
-73,534.0000
-66,048.0000
-19,101.0000
Total Unusual Items Excluding Goodwill
4,543.0000
4,543.0000
292.0000
-3,124.0000
-223.0000
Total Unusual Items
4,543.0000
4,543.0000
292.0000
-3,124.0000
-223.0000
Normalized EBITDA
-42,293.0000
-42,293.0000
-73,759.0000
-61,326.0000
-18,714.0000
12/31/2020 - 4/19/1999
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CYBN Cybin Inc.
0.3500
+1.16%
TENX Tenax Therapeutics, Inc.
3.4800
-0.85%
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
ATAI Atai Life Sciences N.V.
1.9300
+4.89%
GRTX Galera Therapeutics, Inc.
0.1861
-10.31%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1685
+5.31%
SPRB Spruce Biosciences, Inc.
0.7000
-0.14%
NBY NovaBay Pharmaceuticals, Inc.
0.0788
+2.34%
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
VTGN Vistagen Therapeutics, Inc.
4.7500
+1.06%